Biogen Canada Inc. acknowledges the draft recommendation from Canada's Drug Agency (CDA) that supports a significant expansion of public reimbursement for SPINRAZA (nusinersen) for Canadians with spinal muscular atrophy (SMA). (Canada Newswire) - Oct 26, 2026 - "The draft recommendation supports public reimbursement of SPINRAZA for patients with genetically confirmed 5q SMA with 2, 3 or 4 SMN2 gene copies including adults, provided certain conditions are met...it does not result in immediate changes to provincial drug coverage, as provincial funding decisions are still required...The CDA's draft recommendation is open to stakeholder feedback from October 22 to October 29, 2026, with a final recommendation expected on December 1, 2026."
Reimbursement • Genetic Disorders • Muscular Atrophy
|